185 results about "L-tartaric acid" patented technology

The invention relates to an improver for saline-alkali soil. The improver comprises a powder agent and a water agent, wherein the powder agent comprises the following components: organic matters, plant mycelium protein powder, active calcium, calcium superphosphate, aluminum sulfate, fatty alcohol polyoxyethylene ether ammonium sulfate, amino acid powder, bacillus subtilis and photosynthetic bacteria, and the water agent comprises the following components: citric acid, fulvic acid, humic acid, malic acid, maleic acid, fumaric acid, L-tartaric acid, pyrophosphoric acid, humic acid, lactic acid, oxalic acid, salicylic acid, sodium ion adsorbent, Tween-80 and water. The improver disclosed by the invention can improve the soil from multiple angles, namely soil structure, microorganism species, a chemical method and the like, obviously promote the release of iron and phosphorus in the soil, improve the soil structure, effectively reduce the content of sodium ions in the soil, reduce the pH value of the soil and restore land to a normal planting state after being used continuously for two years.

The present disclosure generally relates to methods of preparing nicotine and resolving R,S nicotine to enrich the (S)(−) enantiomer. The method may comprise combining N-methyl-2-pyrrolidone or a salt thereof with a nicotinate compound in the presence of a solvent and a strong base to form 1-methyl-3-nicotinoyl-2-pyrrolidone or a salt thereof; and reducing the 1-methyl-3-nicotinoyl-2-pyrrolidone or salt thereof in solution with Na2S2O4 to produce racemic nicotine or salt thereof. Resolving the racemic nicotine (or other enantiomeric mixture) may comprise combining the nicotine with (−)-O,O′-di-p-toluoyl-L-tartaric acid (L-PTTA).

A therapeutic compound consisting of human telomerase, its catalytic subunit hTert, or a known variant of either, and a biodegradable nanoparticle carrier, which can be administered to cells in a cell culture or in a living animal, is provided herein. The therapeutic compound is envisioned as a method for treating a wide variety of age-related diseases such as idiopathic pulmonary fibrosis, aplastic anemia, dyskeratosis congenita, arteriosclerosis, macular degeneration, osteoporosis, Alzheimer's, diabetes type 2, and any disease that correlates with telomere shortening and may be corrected or ameliorated by lengthening telomeres. The therapeutic compound is also envisioned as method for potentially treating more generic problems of human aging. The nanoparticle carrier is comprised of certain biodegradable biocompatible polymers such as poly(lactide-co-glycolide), poly(lactic acid), poly(alkylene glycol), polybutylcyanoacrylate, poly(methylmethacrylate-co-methacrylic acid), poly-allylamine, polyanhydride, polyhydroxybutyric acid, polycaprolactone, lactide-caprolactone copolymers, polyhydroxybutyrate, polyalkylcyanoacrylates, polyanhydrides, polyorthoester or a combination thereof. The nanoparticle may incorporate a targeting moiety to direct the nanoparticle to a particular tissue type or a location within a cell. The nanoparticle may incorporate a plasticizer to facilitate sustained release of telomerase such as L-tartaric acid dimethyl ester, triethyl citrate, or glyceryl triacetate. A nanoparticle of the present invention can further contain a polymer that affects the charge or lipophilicity or hydrophilicity of the particle. Any biocompatible hydrophilic polymer can be used for this purpose, including but not limited to, poly(vinyl alcohol).

(R,S)-Nicotine was resolved through diastereomeric salt formation using dibenzoyl-d-tartaric acid and dibenzoyl-l-tartaric acid to obtain enantiomerically pure (S)-nicotine and (R)-nicotine.

The present invention provides for a process for preparing racemic methyl 6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylate, its corresponding salt: (2S, 3R, 4S)-methyl 6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylate di-p-toluoyl-D-tartaric acid (“D-DTTA”) salt or a (2R, 3S, 4R)-methyl 6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylate di-p-toluoyl-L-tartaric acid salt (“L-DTTA”) in a high enantiomeric excess. This invention also provides for a process for preparing a (2S, 3R, 4S)-methyl 6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylate dibenzoyl-D-tartaric acid (“D-DBTA”) salt or a (2R, 3S, 4R)-methyl 6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylate L-tartaric acid (“L-DBTA”) salt in a high enantiomeric excess. Further, this invention provides a process for preparing intermediates II, IIB, III, IV, IV salt, V, VI, and VII.

The invention relates to a method for preparing an R-beta-aminobenzene butyric acid derivative (I) serving as a chiral medicament midbody and a pharmaceutically acceptable salt thereof. In the method, chemical synthesis processes including the resolution of a DL body of a beta-aminobenzene butyric acid derivative by using a resolving agent are used to obtain a target matter of a special optical configuration. The preparation method comprises a step of using resolving agents which are di-p-toluoyl-L-tartaric acid and di-p-toluoyl-D-tartaric acid to salify and resolve in an alcohols solvent andan alcohols water solvent. The obtained R-beta-aminobenzene butyric acid derivative (I) has a high optical purity and an accumulated overall yield of the positive and negative resolution of up to over 70 percent. The R-beta-aminobenzene butyric acid derivative (I) prepared by the invention can better applied to synthesizing medicaments.

The invention relates to phosphating liquid of a phosphating process, in particular to phosphating liquid of a high corrosion resistance black phosphating production process for steel piecec, which is characterized in that: the phosphating liquid comprises the following components: 25 to 35 g / L zinc oxide (ZnO), 120 to 135 g / L phosphoric acid H3PO4, 100 to 150 g / L zinc nitrate Zn(NO3)2.6H2O, 5 to 8 g / L nitric acid HNO3, 3 to 5 g / L citric acid, 0.5 to 1 g / L tartaric acid and 5 to 10 g / L nickel nitrate. The phosphating liquid ensures the fineness and smoothness of the phosphating film crystal of the steel piece, has firm attachment, good blackness and high abrasion resistance, and is particularly applicable to the steel components of the optical instrument.

The invention provides a preparation method of lorcaserin hydrochloride, namely (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride. The method comprises the following steps: taking p-chlorophenyl acetate as raw material, performing aminolysis with isopropanol amine, then performing chlorination, reduction and Friedel-Crafts alkylation, further splitting by L-tartaric acid, and performing salt formation to get the lorcaserin hydrochloride. The invention provides the preparation method of the lorcaserin hydrochloride. The method has the advantages of low cost, simplicity in operation and higher product purity; according to the process disclosed by the invention, the continuous operation can be performed, and the production cycle is greatly reduced; meanwhile a reagent is low in price and easy to obtain, the operation is simple, and the post-treatment is simple and convenient, so that the preparation method is a brand new and economic synthesis method which can realize industrial production.

The invention relates to the field of medicine chemistry, aims to solve the problems that the prior art is complex in reaction steps, high in production risk, low in yield, and the like, and provides a synthesizing method of silodosin and an intermediate thereof. The synthesizing method includes: using hydrochloric acid / acetic acid to perform deacetylation on chloride 2 to obtain indoline 3, performing SN2 substitution reaction to obtain imide 4, performing N alkylation reaction to obtain benzoate 5, reducing carbonyl to obtain indoline 6, performing Vilsmeier reaction to obtain aldehyde 7, performing oximation dewatering to obtain nitrile 8, performing hydrazine hydrate reaction to obtain amine 9, performing L-tartaric acid separation on the amine 9 to obtain the silodosin key intermediate 10, performing condensation under an alkaline condition to obtain a compound 11, allowing the compound 11 to have salt formation crystallization with L-malic acid to form salt 12, and performing alkaline hydrogen peroxide hydrolysis on the salt 12 to obtain the silodosin 1. The synthesizing method has the advantages that the L-malic acid is used to perform the salt formation crystallization, impurities such as bipolymer which are hard to remove are removed effectively, high reaction conversion rate is achieved, industrial production cost is lowered effectively, and synthesizing safety is increased by avoiding the use of dangerous reagents.

The present invention provides a sterilization auxiliary for ozone sterilization which is an aqueous solution including a Component (A) of an aluminum compound which produces aluminum ions in an aqueous solution, and a Component (B) of one or more of acids selected from phosphoric acid, citric acid, malic acid, succinic acid, gluconic acid, lactic acid, and L-tartaric acid, wherein the pH of the aqueous solution is greater than or equal to 1.0 and less than 5.0, and an ozone sterilization method for ozone-treating a substance to be treated using the sterilization auxiliary. According to the present invention, a sterilization auxiliary for ozone sterilization in which a high sterilizing effect may be obtained using less ozone without burdening sterilization apparatus and a substance to be treated, and a low-cost ozone sterilization method using the sterilization auxiliary can be provided.

A disinfection aid for ozone disinfection, which consists of an aqueous solution that contains (A) an aluminum compound capable of forming aluminum ions in an aqueous solution and (B) at least one acid selected from among phosphoric acid, acetic acid, citric acid, malic acid, succinic acid, gluconic acid, lactic acid, and L-tartaric acid and that has a pH of 1.0 to less than 5.0; and a method for ozone disinfection, which comprises subjecting an object to be disinfected to ozonization using the disinfection aid. Thus, a disinfection aid which, even when a smaller amount of ozone is used, can ensure high disinfection effect without a load on a disinfection apparatus or an object to be disinfected, and a low-cost method for ozone disinfection using the disinfection aid are provided.